Bvf Inc Concert Pharmaceuticals, Inc. Transaction History

Bvf Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.8 - $6.36 $3.85 Million - $8.75 Million	1,376,000 Added 61.07%	3,629,000 $15.3 Million
Q4 2021 Feb 14, 2022	BUY	$2.69 - $4.22 $6.06 Million - $9.51 Million	2,253,000 New	2,253,000 $7.1 Million
Q3 2019 Nov 14, 2019	SELL	$5.88 - $12.35 $9.57 Million - $20.1 Million	-1,628,187 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.44 - $13.12 $2.29 Million - $3.18 Million	242,700 Added 17.52%	1,628,187 $19.5 Million
Q1 2019 May 15, 2019	BUY	$12.07 - $17.54 $2.84 Million - $4.12 Million	235,042 Added 20.43%	1,385,487 $16.7 Million
Q4 2018 Feb 14, 2019	SELL	$11.25 - $16.17 $4.97 Million - $7.14 Million	-441,693 Reduced 27.74%	1,150,445 $14.4 Million
Q3 2018 Nov 14, 2018	SELL	$12.82 - $17.88 $2.88 Million - $4.02 Million	-225,000 Reduced 12.38%	1,592,138 $23.6 Million
Q2 2018 Aug 14, 2018	SELL	$16.83 - $21.66 $1.94 Million - $2.49 Million	-114,985 Reduced 5.95%	1,817,138 $30.6 Million
Q1 2018 May 07, 2018	SELL	$19.24 - $28.03 $724,693 - $1.06 Million	-37,666 Reduced 1.91%	1,932,123 $44.2 Million
Q4 2017 Feb 14, 2018	SELL	$13.96 - $29.05 $16.3 Million - $33.9 Million	-1,165,500 Reduced 37.17%	1,969,789 $51 Million
Q3 2017 Nov 14, 2017	BUY	$13.91 - $15.31 $43.6 Million - $48 Million	3,135,289	3,135,289 $46.2 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.